New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
10:18 EDTTEX, HSP, BOBE, NFX, EEP, ASML, SNMX, CCE, HWAYHigh option volume stocks:
High option volume stocks: HWAY ASML BOBE CCE ASHR EEP HSP SNMX NFX TEX
News For HWAY;ASML;BOBE;CCE;EEP;HSP;SNMX;NFX;TEX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 24, 2015
16:52 EDTNFXNewfield Exploration cuts 2015 capital budget by 40% to $1.2B
Subscribe for More Information
16:50 EDTNFXNewfield Exploration says Eagle Ford drilling suspended for 2015
Subscribe for More Information
16:50 EDTNFXNewfield Exploration reports Q4 EPS ex-items 38c, consensus 44c
Subscribe for More Information
16:21 EDTHWAYHealthways trades higher after results, levels to watch
Subscribe for More Information
16:02 EDTHWAYHealthways sees 2015 adjusted EPS 35c-47c, consensus 40c
Subscribe for More Information
16:01 EDTHWAYHealthways reports Q4 adjusted EPS 25c, consensus 18c
Subscribe for More Information
07:19 EDTASMLSusquehanna to hold a summit
Subscribe for More Information
February 19, 2015
09:59 EDTTEXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:06 EDTTEXTerex downgraded at BMO Capital
Subscribe for More Information
06:17 EDTHSPHospira Inflectra patient registry reports interim results in treatment of IBD
Data have been presented on the use of Hospira's Inflectra, the world's first approved biosimilar monoclonal antibody, or mAb, at the European Crohn's and Colitis Organisation Inflammatory Bowel Diseases, or ECCO-ibd, conference. Results show a comparable response in patients treated with Inflectra to that expected with the reference product, Remicade, for inducing and maintaining remission in Crohn's disease, or CD, and ulcerative colitis, or UC. These data add to the body of evidence supporting Inflectra's use in inflammatory bowel disease, or IBD. Results presented from the ongoing independent, prospective, nationwide study in Hungary show that for the first 90 patients, treated with Inflectra, reductions compared with baseline were seen in validated measures of disease activity after both two and six weeks of treatment. C-reactive protein, or CRP, a marker of inflammation, was also decreased during induction therapy for UC. Four of the 90 patients showed an allergic reaction to treatment, all of who had previously received anti-TNF medication. The abstract can be found at: P314 Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort.
06:11 EDTTEXTerex downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
February 18, 2015
12:48 EDTEEPEnbridge Energy sees FY15 adjusted EBITDA of $1.68B-$1.78B
Subscribe for More Information
12:45 EDTEEPEnbridge Energy reports Q4 EPS 51c, may not compare to consensus 28c
Reports Q4 operating revenue $2.07B, consensus $1.75B.
08:41 EDTHSPThe Medicines Co. says not giving financial guidance due to Hospira suit
Subscribe for More Information
February 17, 2015
18:36 EDTTEXOn The Fly: After Hours Movers
Subscribe for More Information
17:31 EDTTEXTerex sees FY15 EPS $2.00-$2.30, consensus $2.60
Subscribe for More Information
17:27 EDTTEXTerex reports Q4 adjusted EPS 72c, consensus 68c
Subscribe for More Information
16:32 EDTTEXTerex increases dividend 20% to 6c
Subscribe for More Information
07:15 EDTCCEConsumer Analyst Group of New York (CAGNY) to hold a conference
Subscribe for More Information
04:47 EDTHSPPfenex price target raised to $16 from $12 at Mizuho
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use